The subject has received bevacizumab for their disease unless in the context of primary therapy for newly diagnosed glioma

Patients with newly diagnosed RMS of any subtype, except adult-type pleomorphic, based upon institutional histopathologic classification, are eligible to enroll on the study based upon stage, group, and age, as below

Enrollment on ANBLB or APECB is required for all newly diagnosed patients

Group C: patients <  months (<  days) of age with newly diagnosed INRG stage Ms neuroblastoma/ganglioneuroblastoma

Newly diagnosed patients with histologically proven ALCL (International Classification of Diseases for Oncology [ICD-] code: /)

Subject with histologically or cytologically confirmed extensive-stage disease SCLC which is newly diagnosed and chemotherapy naive

Patients with CNS GCTs who are newly diagnosed are excluded from the study

Newly-diagnosed brain cancer with histopathological diagnosis of GBM;

Newly diagnosed acute myeloid leukemia in older patients (>=  years) not candidates for intensive induction chemotherapy (Cohort )

Histologically confirmed newly diagnosed stage I-II HER/neu positive breast cancer

History of previously treated ipsilateral or contralateral breast carcinoma is not an exclusion criteria if the investigator is certain newly diagnosed carcinoma is new unifocal primary tumor.

Newly diagnosed mature B-lineage (CD positive) Leukemia/Lymphoma

Be newly diagnosed and previously untreated

Prior WBRT for newly diagnosed brain metastases

Treatment naive for his or her newly diagnosed malignancy for enrollment to groups  or 

newly diagnosed AML unsuitable for intensive chemotherapy

For the Phase II part of the study, newly diagnosed OR refractory/metastatic anaplastic thyroid cancer confirmed by histology, incurable by surgery, radiotherapy or chemoradiotherapy alone or in combination

Newly diagnosed, previously untreated participants with rhabdomyosarcoma (RMS)

Patients with biopsy proven newly diagnosed rhabdomyosarcoma

Have newly diagnosed localized or locally advanced (TN-M or T-NanyM), potentially resectable disease without any prior systemic chemotherapy

Group : Must have newly diagnosed, pathologically confirmed cHL at Stages IA, IB and IIA without bulky disease. Group : Must have newly diagnosed, pathologically confirmed cHL at Stages IIEB, IIIEA,IIIEB, IIIB, IVA and IVB

Elderly (>  year old) patients with newly diagnosed AML not eligible for intensive chemotherapy

Newly diagnosed patients who are ineligible or declined to receive intensive chemotherapy after discussion of risks and benefits of that approach or patients with primary refractory/relapsed AML

Newly diagnosed brain cancer or tumor called glioblastoma or GBM

Newly-diagnosed brain cancer or tumor called glioblastoma or GBM

Must have recurrent disease confirmed by MRI (Group ) or completed SoC therapy such as surgery with adjuvant radiochemotherapy with or without maintenance temozolomide according to local standards for newly diagnosed disease (Group )

Patients with newly diagnosed, uncontrolled and or untreated cancer; related central nervous system diseases are excluded.

Newly diagnosed androgen-sensitive metastatic disease; or

Newly diagnosed, treatment naive, HNSCC suitable for surgical resection with planned radiotherapy and/or chemotherapy after surgery

Newly diagnosed histologically proven locoregional OCSCC (T-stage -) without evidence of distant metastases; OCSCC includes the subsites of oral tongue, floor of mouth, gingiva, retromolar trigone, and buccal mucosa

Newly diagnosed, biopsy proven cancer of the endometrium, prostate or breast

Diagnosed with SMM within the last  years

Histopathologically proven newly-diagnosed primary glioblastoma with complete or partial surgical resection; biopsy not acceptable

Newly diagnosed de novo AML; or

Newly diagnosed (non-M) AML patients

No diagnosed arrhythmias

PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Is currently participating or has participated in any other newly diagnosed therapeutic trial before or after chemoradiation

PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Has known gliomatous meningitis, extracranial disease, or multifocal disease

Documented evidence of newly diagnosed, symptomatic MM, by IMWG criteria within five years of enrollment

Newly diagnosed or relapsed participants are eligible to participate; this protocol is intended to enroll both previously treated and untreated patients

Patients must have histologically confirmed newly diagnosed or previously untreated (patients may be under no treatment wait and watch or have received two cycles of chemotherapy or localized radiation therapy before going on this study) non-Hodgkins lymphoma or CLL

Newly diagnosed, histologically confirmed breast cancer

Patients with newly diagnosed AT/RT

Patients with newly diagnosed AT/RT and synchronous extra-CNS MRT

Patient has newly diagnosed disease with no prior therapy

Currently receiving or scheduled to receive any other therapies intended to treat the newly diagnosed glioma prior to the MLA and the first post-MLA blood collection for correlative studies

Any prior treatment for the current, newly diagnosed breast cancer

Patient must have newly diagnosed, histologically confirmed GBM

Patients with newly diagnosed stage I and II nasal NK cell lymphoma

Four or more newly-diagnosed lesions

The patient has newly-diagnosed, biopsy proven squamous cell carcinoma of stage I-IV (T-, N-b) of the oropharynx

In the phase II portion, patients must be newly diagnosed or treatment naive, or have been off adjuvant imatinib therapy for at least  months; patients with newly diagnosed GIST and who had been on imatinib for up to  weeks prior to signing the consent are allowed to enroll in order to expedite accrual

Newly diagnosed MCL: Confirmed diagnosis of MCL with CD and cyclin D positivity in tissue\r\nbiopsy; patients must have never received any prior therapy for their disease

Newly diagnosed MCL: Patients should in general have bi-dimensional measurable disease with\r\ntheir biggest tumor less than  cm; (bone marrow or gastrointestinal [GI] only involvement is acceptable)

Newly diagnosed MCL: Ki protein (Ki) < %

Newly diagnosed MCL: The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patients health and survival, than of the MCL, within the subsequent  months at the time of consent

Newly diagnosed MCL: Prior treatment with ibrutinib

Newly diagnosed MCL: Patients with blastoid and pleomorphic variants

Newly diagnosed MCL: Ki- to be equal or more than %

Newly diagnosed MCL: Central nervous system lymphoma

Newly diagnosed MCL: Patients with bi-dimensional measurable disease with a tumor >=  cm

Patients with newly diagnosed brain metastases are eligible as long as they are not planned for WBRT upfront

Cohort A: newly diagnosed AML, no prior cytotoxic chemotherapy

Newly diagnosed patients with stage I and II follicular lymphoma, pathologically confirmed at MD Anderson Cancer Center (MDACC) to be grade  or 

Untreated, non-transplant eligible, newly diagnosed mantle cell lymphoma with measurable disease as determined by computed tomography (CT), and bone marrow biopsy

Elderly subjects (?  years) with newly diagnosed AML must be treatment naive and unfit for intensive chemotherapy.

Patients with ICGCTs who are newly diagnosed are excluded from the study

Newly diagnosed disease

Has a newly diagnosed tumor and a curative treatment option or approved therapy is available

newly diagnosed untreated AML in patients ?  years of age, if they are not candidates for standard available induction chemotherapy

Subjects with (newly diagnosed or recurrent) metastatic cancer for whom surgery, radiation, or radiosurgery has not been advised by the treating physician.

Newly diagnosed DIPG patients\r\n* Patients must have not received any prior therapy for treatment of their current CNS malignancy other than radiation therapy

PART  PATIENTS (NEWLY DIAGNOSED GBM)

Patients should be newly diagnosed HNSCC, with no prior therapy for this disease

Patients with newly diagnosed GCT

newly diagnosed advanced breast cancer, then relapsed with documented evidence of progression while on or after only one line of endocrine therapy

T.Bili. ? . x ULN (except in patients diagnosed with Gilbert's disease).

Subjects ?  years of age with newly diagnosed AML

Diagnosis of newly diagnosed lymphoblastic lymphoma (patients must have < % tumor cells in bone marrow by morphology)

newly diagnosed advanced/metastatic breast cancer, treatment nave

Patients must either not be a candidate for docetaxel chemotherapy for newly diagnosed metastatic prostate cancer, as determined by their treating oncologist, or have declined this therapy

Diagnosed with PNH

Patients must be newly diagnosed with de novo acute myelogenous leukemia

Patients must be newly diagnosed with histologically-proven hepatoblastoma

Newly diagnosed stage IIIA/B NSCLC, PS -

Patients must not have received any prior treatment for current or newly diagnosed breast cancer

High-risk SMM per Mayo Clinic or Spanish PETHEMA (Treatment of Newly Diagnosed Patients with Acute Promyelocytic Leukemia) criteria

Newly diagnosed, biopsy-proven stage -II breast cancer

Is newly diagnosed with a curative treatment option available.

INCLUSION CRITERIA FOR NEWLY DIAGNOSED PATIENTS WITH DIPG

EXCLUSION CRITERIA FOR NEWLY DIAGNOSED PATIENTS WITH DIPG

Newly diagnosed elderly AML patients (>  years) unfit for intensive chemotherapy with cytarabine and anthracyclines are also eligible to this trial given that no clinically beneficial therapy exists for these patients

Newly diagnosed or uncontrolled cancer-related central nervous system disease

COHORT A: The subject must have newly diagnosed prostate cancer with a metastatic site(s)

Subjects must be newly diagnosed or previously diagnosed with CNL or aCML; all patients must have a bone marrow biopsy completed during the screening or baseline period if one has not been done within  days of day , cycle one

Subjects who have been diagnosed with indolent NHL that has progressed.

Patients with newly diagnosed, CD-positive mature T-cell lymphomas

Patients with newly diagnosed PVNS with, at least, one measurable site of disease on MRI.

Pre- and post-menopausal women newly diagnosed with DCIS histologically confirmed on breast core biopsy

Newly diagnosed patients with no prior attempt at curative therapy

Newly diagnosed, previously untreated patients with histologically or molecularly confirmed DSRCT

Tumor: newly diagnosed non-disseminated diffuse intrinsic pontine glioma based on clinical AND radiographic finding

Patients must have  or fewer newly diagnosed metastatic lesions in the brain with a complete resection of at least one lesion as determined by the study neuroradiologist

Newly diagnosed, treatment naive CP-CML (Cohort )

Newly diagnosed disease

Patients who are newly diagnosed should have not received any other chemotherapeutic therapy (with the exception of dexamethasone)  week before starting, or radiation therapy,  weeks before starting

Biopsy-proven KS involving skin, with or without visceral involvement, either newly diagnosed or refractory to or intolerant of one or more prior therapies

Subjects must have newly diagnosed (within  years), previously untreated prostate cancer without concurrent malignancy

Newly diagnosed cGVHD defined by:

Newly diagnosed inoperable cervical cancer treated with chemoradiation therapy with curative intent and life expectancy of at least  months as assessed by the investigator o No CNS/spinal metastases

Newly diagnosed patients with unilateral group D retinoblastoma

Newly diagnosed, previously untreated patients with histologically or molecularly confirmed Ewing sarcoma

Patients must have newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases

Arm B: Patients with CML in AP or BP, either newly diagnosed or failing TKI therapy (i.e., Acute Group patients);

Newly diagnosed patients who have not received prior therapy, with the exception of one short course of emergent chemotherapy in newly presenting patients with neurological compromise per provider decision

Documented evidence of symptomatic MM, either newly diagnosed or relapsed/refractory

Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue.

Have newly diagnosed localized or locally advanced (TN-M or T-NanyM), potentially resectable disease without any prior systemic chemotherapy

Patients with - newly diagnosed brain metastases

The child must be a newly diagnosed patient with any type of malignant disease who will be or is receiving chemotherapy and/or radiation therapy

Patient must be newly diagnosed or relapsed/progressed with a brain tumor that has not previously been treated with CRT\r\n* Note: COG therapeutic study participation is not required for ACCLP enrollment

Diagnosed with ALL

Individuals who have been diagnosed with lung cancer\r\n* Individuals are eligible regardless of date of diagnosis (newly diagnosed or long-term survivor), pathology type or stage of lung cancer, or history of other cancers

Newly diagnosed prostate cancer (PCa) (within -months).

The patient must not have received bevacizumab as an upfront treatment in newly diagnosed glioblastoma.

Patients diagnosed with T-cell Lymphomas.

Are newly diagnosed with prostate cancer

Newly diagnosed solid tumor or lymphoma with histological verification

A newly diagnosed, histologically proven cancer arising from the oral cavity and oropharynx

Newly diagnosed, in need of a new line or therapy, or at a treatment decision making timepoint.

PATIENTS: Newly diagnosed with any stage cancer

Patients who are newly diagnosed with acute leukemia and hospitalized to receive their initial  weeks of intensive induction chemotherapy for this disease

Newly diagnosed with stage  or higher cervical cancer within the past  months

Newly diagnosed with any stage of uterine cancer (both sarcoma and carcinosarcoma) in the past  months

Be diagnosed with cancer

Newly diagnosed adult cancer patients from VICC and MMC or a participating caregiver designated by the patient

Patient must be newly diagnosed (i.e., not relapsed) with any malignancy

Patients with newly diagnosed or recurrent gynecologic cancer (ovarian, uterine, cervical, vaginal, vulvar) actively undergoing treatment (chemotherapy, surgery, or radiation therapy) at COH (including Duarte and South Pasadena campuses)

newly diagnosed with I-III non-metastatic cancer

Newly diagnosed with acute leukemia by pathology report

Participants must be diagnosed with cancer

Women who have been newly diagnosed with a first primary, epithelial ovarian cancer, have undergone surgical debulking and who will be treatment according to the Armstrong method

Newly diagnosed, primary, epithelial ovarian cancer

Newly diagnosed breast cancer patients

Patient must be a newly diagnosed ALL, in first remission

All patients with newly diagnosed lymphoma

Newly diagnosed stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a >  year life expectancy

Men newly diagnosed with prostate cancer who are scheduled for prostatectomy (stage T or T)

Newly diagnosed tumors: patients with newly diagnosed grade IV glioma who have had not been previously treated with cranial radiation therapy

Newly diagnosed breast cancer patients

Newly diagnosed primary brain tumor of any location and any histology (Cohort )

Patients must have histologically or cytologically proven advanced non-squamous NSCLC; patients may have newly diagnosed recurrent progressive or refractory disease which may be localized or wide spread

Patients with histologically confirmed malignancy (local or metastatic, newly diagnosed or recurrent disease)

Diagnosed with hypotonia

An adult patient with a newly diagnosed, untreated primary lung cancer diameter  mm or more; AND

Have one of the following disease histories: \r\n* Newly-diagnosed or recurrent (local, regional, metastatic) malignant melanoma or breast cancer patients in whom SLN mapping is indicated \r\n** Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas \r\n** Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region\r\n** Newly-diagnosed patients with previous excisional biopsy OR \r\n** Newly-diagnosed gynecologic cancer patients in whom SLN mapping and surgical excision is indicated

Newly diagnosed, untreated mass in posterior fossa, either benign or malignant

Newly-diagnosed or recurrent (local, regional, metastatic) metastatic melanoma or malignant brain tumor patients with:\r\n* Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas, or malignant brain tumor\r\n* Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region\r\n* Newly diagnosed patients with previous excisional biopsy

Newly diagnosed with esophageal cancer.

Patient is diagnosed with cancer

Be diagnosed with T or greater LABC, any N and M.

Patients with newly diagnosed and untreated stage II and II breast cancer scheduled to undergo neoadjuvant chemotherapy

Patients who will be undergoing surgery for newly-diagnosed glioblastoma

Women must have newly diagnosed histologically or cytologically confirmed endometrial cancer

Have newly diagnosed infiltrating ductal carcinoma of the breast

All cancer types and both newly diagnosed and previously treated patients will be included

Newly diagnosed with clinically node-negative breast cancer or melanoma being staged with SLN biopsy

Patients with newly diagnosed, relapsed, or refractory EBV-associated or KSHV-associated malignancies including human immunodeficiency virus (HIV)-associated lymphomas are potentially eligible

Hospitalized for newly diagnosed acute leukemia

Be diagnosed with a neurodegenerative disease

Providing surgical treatment for newly diagnosed breast cancer patients

PHASE II: Women newly diagnosed with breast cancer on the day they meet with their surgeon for their initial consultation after the visit

Newly diagnosed breast cancer

Newly diagnosed suspected or proven clinical stage I NSCLC (T or T, N, M) with no prior treatment for this disease

Histologically confirmed newly diagnosed G MG

Patients must have suspected refractory or relapsed pre-B cell ALL or mixed phenotype acute leukemia (MPAL), or if newly diagnosed, the patient must be  years of age or older

Newly diagnosed, de novo or secondary, previously untreated AML

Participants must have progressive, advanced cancer as defined by one of the following:\r\n* Newly diagnosed, untreated advanced disease\r\n* Newly diagnosed, untreated metastatic recurrence of earlier stage disease (previous treatment of early stage disease allowed)\r\n* Clinical determination of progressive disease on previous systemic therapy as evidenced by plan to change treatment; any number of prior therapies are acceptable excluding previous EGFR kinase inhibitors